Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab

The association between natalizumab and progressive multifocal leukoencephalopathy (PML) is established, but a reliable clinical risk stratification flow-chart is lacking. New risk factors are needed, such as the possible role of the anti-JC polyomavirus (JCPyV) neutralizing antibody. In this pilot...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Roberta Antonia Diotti, Ruggero Capra, Lucia Moiola, Valeria Caputo, Nicola De Rossi, Francesca Sangalli, Vittorio Martinelli, Roberto Burioni, Massimo Clementi, Nicasio Mancini
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2016-05-01
Serie:	Viruses
Soggetti:	multiple sclerosis natalizumab progressive multifocal leukoencephalopathy humoral response
Accesso online:	http://www.mdpi.com/1999-4915/8/5/128
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!